• Viewed 10,240 times by 3014 users (Last 30 days)
  • print Created with Sketch. Print
BTA
Click for more information
0.00% 57.0¢

BIOTA HOLDINGS LIMITED - Announcements

Currently unlisted. watchlist Created with Sketch. Add to my watchlist

Corporate Spotlight
Not Yet Available

Are you a Company Director ?
Put your Investment Case to Hotcopper's 700K monthly unique visitors.

Claim your IR profile arrow Created with Sketch.
See benefits

Announcements


Plus500
Plus500
ANNOUNCEMENT SPONSORED BY PLUS500
ANNOUNCEMENT SPONSORED BY PLUS500
CFD TRADING PLATFORM
CFD Service. Your Capital is at risk
CFD TRADING PLATFORM CFD Service. Your Capital is at risk
TRADE NOW
TRADE NOW
Plus500
ANNOUNCEMENT SPONSORED BY PLUS500
CFD TRADING PLATFORM CFD Service. Your Capital is at risk
TRADE NOW

Filter Results
All Price Sensitive Only
search Created with Sketch. Search
search Created with Sketch. Search
BTA2010 AGM Results - resubmitted23/11/10
BTAFinal Director's Interest Notice22/11/10
BTA2010 AGM Results22/11/10
BTA2010 AGM Addresses22/11/10
BTAAppendix 3Y-Change of Director's Interest Notice11/11/10
BTAShares released from escrow11/11/10
BTACleansing Statement22/10/10
BTAAppendix 3B22/10/10
BTARelenza September Quarter RoyaltyPRICE SENSITIVE22/10/10
BTAInavir launch in JapanPRICE SENSITIVE19/10/10
BTANotice of Annual General Meeting/Proxy Form18/10/10
BTAAppendix 3B05/10/10
BTAInavir launch in Japan29/09/10
BTAInavir approved for sale in JapanPRICE SENSITIVE13/09/10
BTA +Change in substantial holding from HHL07/09/10
BTAAppendix 3Y - Change of Director's Interest Notice03/09/10
BTAAnnual Report to shareholders23/08/10
BTAAppendix 3B19/08/10
BTAOpen Briefing - CEO on FY10 results18/08/10
BTAPreliminary Final ReportPRICE SENSITIVE18/08/10
BTAHRV Phase II trial underway in patientsPRICE SENSITIVE26/07/10
BTARoyalties from Relenza for Q4 and F2010PRICE SENSITIVE22/07/10
BTAAppendix 3B08/07/10
BTAAppendix 3B29/06/10
BTAAppendix 3B25/05/10
BTARelenza royalty for March 2010 quarterPRICE SENSITIVE29/04/10
BTACleansing Statement27/04/10
BTAAppendix 3B - New Share Issue27/04/10
BTAHCV research agreement concludesPRICE SENSITIVE20/04/10
BTABiota completes asset purchase form MaxThera, Inc04/03/10
BTAOpen Briefing - H1 10 Result CEO on Outlook17/02/10
BTABiota announces half year net profit of $33.5mPRICE SENSITIVE17/02/10
BTARelenza royalty for December 2009 quarterPRICE SENSITIVE05/02/10
BTACS-8958 NDA filed in Japan01/02/10
BTAAppendix 3B - New share issue01/02/10
BTAAppendix 3X Initial Director's Interest Notice01/02/10
BTABiota appoints new Director01/02/10
BTAAppendix 3Y - Change of Directors Interest Notice I Gust11/01/10
BTAAppendix 3Y - Change of Director's Interest Notice23/12/09
BTAResponse to ASX QueryPRICE SENSITIVE15/12/09
AAD +SandP Announces December SP/ASX Index Rebalance04/12/09
BTACleansing statement12/11/09
BTA2009 AGM Results12/11/09
BTA2009 AGM AddressesPRICE SENSITIVE12/11/09
BTAReturn to shareholders - update12/11/09
BTABiota acquires the antibacterial assets of MaxThera IncPRICE SENSITIVE12/11/09
BTAAppendix 3B12/11/09
BTABiota acquires the antibacterial assets of Prolysis LtdPRICE SENSITIVE12/11/09
BTACS-8958 Phase III prevention study underwayPRICE SENSITIVE05/11/09
BTARelenza Q1 RoyaltyPRICE SENSITIVE29/10/09
BTAChange in substantial holding from HHL28/10/09
BTAAppendix 3B26/10/09
BTANotice of General Meeting/Proxy Form30/09/09
BTAChange in substantial holding from HHL19/08/09
BTALetter to Shareholders19/08/09
BTAOpen Briefing-CEO on F09 Results and Capital ReturnPRICE SENSITIVE19/08/09
BTABiota delivers net profit after tax of $38.2 million19/08/09
BTA2009 Preliminary Final Report and Annual ReportPRICE SENSITIVE19/08/09
BTABiota to return $20 million to shareholdersPRICE SENSITIVE13/08/09
BTALANI Phase III clinical trials in Asia prove successfulPRICE SENSITIVE10/08/09
BTARSV program returned to BiotaPRICE SENSITIVE10/08/09
BTAGSK Relenza capacity to triplePRICE SENSITIVE23/07/09
BTARelenza Q4 royalties $8.9 millionPRICE SENSITIVE23/07/09
BTAAppendix 3B13/07/09
BTACeasing to be a substantial holder06/07/09
BTAOptions Lapsing30/06/09
BTABecoming a substantial holder11/06/09
BTAHRV phase IIa study achieves clinical proof-of-conceptPRICE SENSITIVE11/06/09
BTACeasing to be a substantial holder10/06/09
BTAAustralia adds 1.6m Relenza courses to National StockpilePRICE SENSITIVE29/05/09
BTAImportant GSK initiatives to new influenza A (H1N1) strainPRICE SENSITIVE04/05/09
BTARelenza Q3 royalty $32.3mPRICE SENSITIVE23/04/09
BTAResponse to an ASX QueryPRICE SENSITIVE22/04/09
BTAChange of Director's Interest Notice06/04/09
BTADaiichi Sankyo exercise right to CS-8958 in JapanPRICE SENSITIVE30/03/09
BTAChange in substantial holding24/03/09
BTAFinal Director's Interest Notice02/03/09
BTABiota appoints new Chairman02/03/09
BTAInitial Director's Interest Notice02/03/09
BTAOpen Briefing - CEO on H1 Result and OutlookPRICE SENSITIVE18/02/09
BTABiota announces half year profitPRICE SENSITIVE18/02/09
BTARevised Relenza Royalty Dec 2008PRICE SENSITIVE13/02/09
BTAGSK imports additional Relenza to JapanPRICE SENSITIVE11/02/09
BTARelenza royalty for December 2008 quarterPRICE SENSITIVE06/02/09
BTAUK orders 10.6m Relenza coursesPRICE SENSITIVE30/01/09
BTAChange in substantial holding22/12/08
BTAAppendix 3Y Change of Director's Interest Notice P Cook19/12/08
BTAAppendix 3Z-Final Director's Interest Notice-B Gibson17/12/08
BTADirector Resignation17/12/08
BTAAppendix 3Y - B Gibson08/12/08
BTAInitial Director's Interest Notice28/11/08
BTABiota appoints new director28/11/08
BTADirector appoints new director28/11/08
BTA2010 AGM Results - resubmitted
23/11/10
BTAFinal Director's Interest Notice
22/11/10
BTA2010 AGM Results
22/11/10
BTA2010 AGM Addresses
22/11/10
BTAAppendix 3Y-Change of Director's Interest Notice
11/11/10
BTAShares released from escrow
11/11/10
BTACleansing Statement
22/10/10
BTAAppendix 3B
22/10/10
BTARelenza September Quarter Royalty
22/10/10PRICE SENSITIVE
BTAInavir launch in Japan
19/10/10PRICE SENSITIVE
BTANotice of Annual General Meeting/Proxy Form
18/10/10
BTAAppendix 3B
05/10/10
BTAInavir launch in Japan
29/09/10
BTAInavir approved for sale in Japan
13/09/10PRICE SENSITIVE
BTA +Change in substantial holding from HHL
07/09/10
BTAAppendix 3Y - Change of Director's Interest Notice
03/09/10
BTAAnnual Report to shareholders
23/08/10
BTAAppendix 3B
19/08/10
BTAOpen Briefing - CEO on FY10 results
18/08/10
BTAPreliminary Final Report
18/08/10PRICE SENSITIVE
BTAHRV Phase II trial underway in patients
26/07/10PRICE SENSITIVE
BTARoyalties from Relenza for Q4 and F2010
22/07/10PRICE SENSITIVE
BTAAppendix 3B
08/07/10
BTAAppendix 3B
29/06/10
BTAAppendix 3B
25/05/10
BTARelenza royalty for March 2010 quarter
29/04/10PRICE SENSITIVE
BTACleansing Statement
27/04/10
BTAAppendix 3B - New Share Issue
27/04/10
BTAHCV research agreement concludes
20/04/10PRICE SENSITIVE
BTABiota completes asset purchase form MaxThera, Inc
04/03/10
BTAOpen Briefing - H1 10 Result CEO on Outlook
17/02/10
BTABiota announces half year net profit of $33.5m
17/02/10PRICE SENSITIVE
BTARelenza royalty for December 2009 quarter
05/02/10PRICE SENSITIVE
BTACS-8958 NDA filed in Japan
01/02/10
BTAAppendix 3B - New share issue
01/02/10
BTAAppendix 3X Initial Director's Interest Notice
01/02/10
BTABiota appoints new Director
01/02/10
BTAAppendix 3Y - Change of Directors Interest Notice I Gust
11/01/10
BTAAppendix 3Y - Change of Director's Interest Notice
23/12/09
BTAResponse to ASX Query
15/12/09PRICE SENSITIVE
AAD +SandP Announces December SP/ASX Index Rebalance
04/12/09
BTACleansing statement
12/11/09
BTA2009 AGM Results
12/11/09
BTA2009 AGM Addresses
12/11/09PRICE SENSITIVE
BTAReturn to shareholders - update
12/11/09
BTABiota acquires the antibacterial assets of MaxThera Inc
12/11/09PRICE SENSITIVE
BTAAppendix 3B
12/11/09
BTABiota acquires the antibacterial assets of Prolysis Ltd
12/11/09PRICE SENSITIVE
BTACS-8958 Phase III prevention study underway
05/11/09PRICE SENSITIVE
BTARelenza Q1 Royalty
29/10/09PRICE SENSITIVE
BTAChange in substantial holding from HHL
28/10/09
BTAAppendix 3B
26/10/09
BTANotice of General Meeting/Proxy Form
30/09/09
BTAChange in substantial holding from HHL
19/08/09
BTALetter to Shareholders
19/08/09
BTAOpen Briefing-CEO on F09 Results and Capital Return
19/08/09PRICE SENSITIVE
BTABiota delivers net profit after tax of $38.2 million
19/08/09
BTA2009 Preliminary Final Report and Annual Report
19/08/09PRICE SENSITIVE
BTABiota to return $20 million to shareholders
13/08/09PRICE SENSITIVE
BTALANI Phase III clinical trials in Asia prove successful
10/08/09PRICE SENSITIVE
BTARSV program returned to Biota
10/08/09PRICE SENSITIVE
BTAGSK Relenza capacity to triple
23/07/09PRICE SENSITIVE
BTARelenza Q4 royalties $8.9 million
23/07/09PRICE SENSITIVE
BTAAppendix 3B
13/07/09
BTACeasing to be a substantial holder
06/07/09
BTAOptions Lapsing
30/06/09
BTABecoming a substantial holder
11/06/09
BTAHRV phase IIa study achieves clinical proof-of-concept
11/06/09PRICE SENSITIVE
BTACeasing to be a substantial holder
10/06/09
BTAAustralia adds 1.6m Relenza courses to National Stockpile
29/05/09PRICE SENSITIVE
BTAImportant GSK initiatives to new influenza A (H1N1) strain
04/05/09PRICE SENSITIVE
BTARelenza Q3 royalty $32.3m
23/04/09PRICE SENSITIVE
BTAResponse to an ASX Query
22/04/09PRICE SENSITIVE
BTAChange of Director's Interest Notice
06/04/09
BTADaiichi Sankyo exercise right to CS-8958 in Japan
30/03/09PRICE SENSITIVE
BTAChange in substantial holding
24/03/09
BTAFinal Director's Interest Notice
02/03/09
BTABiota appoints new Chairman
02/03/09
BTAInitial Director's Interest Notice
02/03/09
BTAOpen Briefing - CEO on H1 Result and Outlook
18/02/09PRICE SENSITIVE
BTABiota announces half year profit
18/02/09PRICE SENSITIVE
BTARevised Relenza Royalty Dec 2008
13/02/09PRICE SENSITIVE
BTAGSK imports additional Relenza to Japan
11/02/09PRICE SENSITIVE
BTARelenza royalty for December 2008 quarter
06/02/09PRICE SENSITIVE
BTAUK orders 10.6m Relenza courses
30/01/09PRICE SENSITIVE
BTAChange in substantial holding
22/12/08
BTAAppendix 3Y Change of Director's Interest Notice P Cook
19/12/08
BTAAppendix 3Z-Final Director's Interest Notice-B Gibson
17/12/08
BTADirector Resignation
17/12/08
BTAAppendix 3Y - B Gibson
08/12/08
BTAInitial Director's Interest Notice
28/11/08
BTABiota appoints new director
28/11/08
BTADirector appoints new director
28/11/08
refresh Created with Sketch. REFRESH
 

Top Stories

InhaleRX gains approval for clinical trial to test non-opioid therapy for cancer pain

InhaleRX Ltd has received approval for a Phase 2 clinical trial to test its novel therapy IRX-211 for treatment of Breakthrough Cancer Pain
NT Gov't delivers environmental approval for Empire Energy's Beetaloo Carpentaria pilot gas play Empire Energy (ASX:EEG) has confirmed the NT government has delivered environmental approvals for Carpentaria.
Bigtincan's Board backs Investcorp offer: Why a NASDAQ listing could be game-changing Bigtincan Holdings has fielded an offer from Investcorp. But if you think it's underwhelming – consider Wall Street volumes.
Cyclone signs MOU with Vale for development of Iron Bear play Cyclone Metals Lt has signed a Memorandum of Understanding with Vale S.A to support development of the former's iron ore project in Canada
CuFe sells its Crossroads gold royalty to Northern Star for $4M cash; says better than waiting for mine launch CuFe Ltd (ASX:CUF) has decided not to wait around for Northern Star's Crossroads mine to get up and running, selling its $4M royalty right.
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.